BR112022008610A2 - Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação - Google Patents
Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamaçãoInfo
- Publication number
- BR112022008610A2 BR112022008610A2 BR112022008610A BR112022008610A BR112022008610A2 BR 112022008610 A2 BR112022008610 A2 BR 112022008610A2 BR 112022008610 A BR112022008610 A BR 112022008610A BR 112022008610 A BR112022008610 A BR 112022008610A BR 112022008610 A2 BR112022008610 A2 BR 112022008610A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammation
- treatment
- conditions characterized
- compositions including
- topical compositions
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931132P | 2019-11-05 | 2019-11-05 | |
| US202063046143P | 2020-06-30 | 2020-06-30 | |
| PCT/US2020/059200 WO2021092239A1 (en) | 2019-11-05 | 2020-11-05 | Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008610A2 true BR112022008610A2 (pt) | 2022-08-09 |
Family
ID=73654894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008610A BR112022008610A2 (pt) | 2019-11-05 | 2020-11-05 | Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230125380A1 (https=) |
| EP (1) | EP4054573A1 (https=) |
| JP (1) | JP2023500707A (https=) |
| CN (2) | CN114929223A (https=) |
| AU (1) | AU2020380921A1 (https=) |
| BR (1) | BR112022008610A2 (https=) |
| CA (1) | CA3159624A1 (https=) |
| IL (1) | IL292689A (https=) |
| WO (1) | WO2021092239A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021300110A1 (en) * | 2020-06-30 | 2023-02-02 | Dermira, Inc. | IRAK4 inhibitors and topical uses thereof |
| CN116675780B (zh) * | 2023-06-02 | 2024-07-09 | 东北农业大学 | 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015068856A1 (en) | 2013-11-08 | 2015-05-14 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| JP2018524372A (ja) * | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| WO2017205762A1 (en) * | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| US11167043B2 (en) * | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| AU2021300110A1 (en) * | 2020-06-30 | 2023-02-02 | Dermira, Inc. | IRAK4 inhibitors and topical uses thereof |
-
2020
- 2020-11-05 CA CA3159624A patent/CA3159624A1/en active Pending
- 2020-11-05 WO PCT/US2020/059200 patent/WO2021092239A1/en not_active Ceased
- 2020-11-05 CN CN202080087596.7A patent/CN114929223A/zh active Pending
- 2020-11-05 AU AU2020380921A patent/AU2020380921A1/en active Pending
- 2020-11-05 JP JP2022526059A patent/JP2023500707A/ja not_active Ceased
- 2020-11-05 CN CN202410650258.XA patent/CN118806758A/zh active Pending
- 2020-11-05 US US17/771,777 patent/US20230125380A1/en not_active Abandoned
- 2020-11-05 BR BR112022008610A patent/BR112022008610A2/pt unknown
- 2020-11-05 EP EP20817122.3A patent/EP4054573A1/en not_active Withdrawn
-
2022
- 2022-05-02 IL IL292689A patent/IL292689A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021092239A1 (en) | 2021-05-14 |
| IL292689A (en) | 2022-07-01 |
| US20230125380A1 (en) | 2023-04-27 |
| EP4054573A1 (en) | 2022-09-14 |
| JP2023500707A (ja) | 2023-01-10 |
| CA3159624A1 (en) | 2021-05-14 |
| AU2020380921A1 (en) | 2022-05-26 |
| CN114929223A (zh) | 2022-08-19 |
| CN118806758A (zh) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4360713A3 (en) | Quinazoline derivatives as antitumor agents | |
| CO2026004964A2 (es) | Moduladores de kras | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
| BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
| ECSP23057264A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| MX2022008478A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| CO2021015622A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола | |
| BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
| BR112022008610A2 (pt) | Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação | |
| CL2019003562A1 (es) | Derivados esteroideos con actividad terapéutica. | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| BR112018071064A2 (pt) | prevenção de eventos ateroscleróticos com inibidores diretos de fator xa. | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| BR112022027083A2 (pt) | Inibidores de rorgamat e usos tópicos dos mesmos | |
| BR112022008607A2 (pt) | Inibidores de ror gama t e usos tópicos dos mesmos | |
| ZA202305383B (en) | Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases | |
| BR112022027086A2 (pt) | Inibidores de irak4 e usos tópicos dos mesmos | |
| TR200906775A1 (tr) | Nimesulid ve kas gevşetici kombinasyonları | |
| BR112022020755A2 (pt) | Uso de uma composição farmacêutica |